← Human Trials & Peer-Reviewed Studies
Sexually transmitted infections among women randomised to depot medroxyprogesterone acetate, a copper intrauterine device or a levonorgestrel implant.
Plain-language guide to PMID 33208512 (2021): randomized controlled trial of Copper (Supplement) in 7829 women.
Key Facts
- PMID
- 33208512
- Journal
- Sexually transmitted infections
- Year
- 2021
- Study type
- Randomized Controlled Trial
- Authors
- Deese J et al. (18 authors)
- DOI
- 10.1136/sextrans-2020-054590
What This Study Did, in Plain Language
What Was Tested
Researchers studied Copper (Supplement) in this randomized controlled trial publication.
Reproductive aged women are at risk of pregnancy and sexually transmitted infections (STI).
The researchers compared the risk of STI among women randomised to three contraceptive methods.
The researchers conducted a secondary analysis to assess the risk of chlamydia and gonorrhoea in a clinical trial evaluating HIV risk among 7829 women aged 16-35 randomised to intramuscular depot medroxyprogesterone acetate (DMPA-IM), a copper intrauterine device (IUD) or a levonorgestrel (LNG) implant.
Who Took Part
The abstract describes 7829 women taking part.
The age groups tagged for this paper are teenagers, young adults and adults, women only.
How the Study Was Run
The design is described as randomized.
Because people in this Copper (Supplement) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
The researchers estimated chlamydia and gonorrhoea prevalences by contraceptive group and prevalence ratios (PR) using log-binomial regression.
What Was Measured
The subject headings attached to it are Africa, Chlamydia Infections, Contraception, Contraceptive Agents, Female, Disease Susceptibility, Drug Implants and Gonorrhea.
Author keywords: chlamydia trachomatis, clinical trials and neisseria gonorrhoeae.
What This Means in Plain Language
The paper is a randomized study of Copper (Supplement) in 7829 women.
With several hundred people or more, it is a fairly large study for this kind of research.
The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2021 (Sexually transmitted infections), a journal based in England.
More context: the Copper (Supplement) compound page, all human trials.
Our Notes on the Compound
Copper (Supplement): The active site of cytochrome c oxidase is described as containing copper ions that are essential for electron transfer.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.